All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1…
Roche moves obesity drug to pivotal trials after mid-stage success
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
UnitedHealth Group (UNH) earnings Q4 2025
UnitedHealth Group Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US,…
Japan to designate eight ingredients for list of drugs with abuse risk
The health ministry will designate eight drug ingredients as having abuse potential under the law in response to…
Next steps for Eli Lilly, Novo Nordisk, Pfizer
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George…
Carney, Macron and Chinese windfarms come under fire
US President Donald Trump gestures as he delivers a special address during the World Economic Forum (WEF) annual…
Number of new U.S. drug shortages hits lowest level in 20 years
The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…
Novo Nordisk, Pfizer execs weigh in
President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, Dec.…
Bariatric surgery beats GLP-1s for type 2 diabetes, study finds
When endocrinologist Mary Elizabeth Patti looks at a patient with type 2 diabetes who could benefit from weight…
Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…
Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead
Published: Jan. 15, 2026 at 11:51 a.m. ET Millions of Americans have tried GLP-1s, but some people find that…